Medical Equipment

Global Inactivated Influenza Vaccine Market Size Projected to Reach $9.77 Billion During the Forecast Period

November 18, 2025 by Marketing Posting

Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

By How Much Is The Inactivated Influenza Vaccine Market Expected To Expand Between 2025 And 2029?

The inactivated influenza vaccine sector has exhibited robust expansion recently, projected to increase its valuation from 6.62 billion US dollars in 2024 to 7.14 billion US dollars next year, reflecting a compound annual growth rate of 7.8%. This historical upward trend is largely attributable to several key factors, including a surge in seasonal influenza occurrences, proactive governmental immunization drives, the increasing proportion of the older demographic, enhanced public health knowledge, and the betterment of healthcare facilities.

The market for inactivated influenza vaccines anticipates considerable expansion in the coming years, projected to reach a valuation of $9.77 billion by 2029, reflecting an 8.1 percent compound annual growth rate across the forecast duration, which is fueled by escalating requirements for quadrivalent options, the broadening scope of vaccination initiatives, a heightened emphasis on readiness for potential pandemics, progress in vaccine manufacturing technology, and improved worldwide availability of vaccines, while key observable patterns during this timeframe involve a movement towards vaccine creation methods utilizing cell cultures, the increasing utilization of formulations bolstered by adjuvants, the combining of influenza shots with COVID-19 boosters, growing consumption within developing economies, and the progression of individualized vaccine creation approaches.

Unlock Your Free Sample Report for Exclusive Market Data:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24251&type=smp

Which Drivers Are Impacting The Inactivated Influenza Vaccine Market?

Advancing governmental initiatives focused on immunization are anticipated to be the primary catalyst fueling the expansion of the market for non-live influenza vaccines across the coming period.Due to a growing mindfulness regarding public well-being among citizens, these state-sponsored immunization efforts are broadening, thereby boosting the need for inoculation services and prompting governing bodies to amplify vaccine availability and awareness campaigns.These public health programs actively support the distribution of killed influenza vaccines via affording cost-free or partially funded entry points for vulnerable demographics, thus securing fair protection through vaccination and lessening the impact associated with yearly flu outbreaks.As an illustration, in the twelfth month of 2023, the United Kingdom’s National Health Service, a state-run organization, launched a specific vaccine blueprint aimed at achieving stated immunization targets, which features provisions for localized vaccination centers, especially directed toward populations facing barriers to access.Consequently, the ongoing proliferation of these state-backed vaccination drives serves as a major impetus for the expansion witnessed in the inactivated influenza vaccine sector.

What Are The Major Segments Identified In The Inactivated Influenza Vaccine Market?

The inactivated influenza vaccinemarket covered in this report is segmented –

1) By Type Of Vaccine: Trivalent Inactivated Influenza Vaccine (TIIV), Quadrivalent Inactivated Influenza Vaccine (QIIV)

2) By Application: Children, Adolescence, Adults, Elderly

3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Public Health Clinics

4) By End-User: Healthcare Providers, Individuals, Government Organizations, Pharmaceutical Companies

Subsegments:

1) Trivalent Inactivated Influenza Vaccine (TIIV): Egg-based Trivalent Inactivated Influenza Vaccine, Cell-based Trivalent Inactivated Influenza Vaccine, Adjuvanted Trivalent Inactivated Influenza Vaccine, High-dose Trivalent Inactivated Influenza Vaccine

2) Quadrivalent Inactivated Influenza Vaccine (QIIV): Egg-based Quadrivalent Inactivated Influenza Vaccine, Cell-based Quadrivalent Inactivated Influenza Vaccine, Adjuvanted Quadrivalent Inactivated Influenza Vaccine, Recombinant Quadrivalent Inactivated Influenza Vaccine, Pediatric Quadrivalent Inactivated Influenza Vaccine

What Long-Term Trends Will Shape The Future Growth Of The Inactivated Influenza Vaccine Industry?

Key players within the realm of inactivated influenza vaccines are concentrating their efforts on engineering quadrivalent inactivated influenza vaccines to deliver augmented defense spanning four distinct influenza virus lineages. This quadrivalent inactivated influenza vaccine represents an immunization injection affording coverage against four separate influenza viruses. To illustrate, in February of 2025, Zydus Lifesciences, a pharmaceutical corporation headquartered in India, successfully introduced VaxiFlu-4, a type of quadrivalent inactivated influenza vaccine formulated to supply protection across the seasons from four emerging virus variants. VaxiFlu-4 furnishes wider safeguarding by encompassing both influenza A and B subtypes, thereby mitigating the potential for a situation where the vaccine’s antigens do not align with circulating strains. The objective behind this vaccine is to combat seasonal influenza epidemics through an enhanced immunological response specifically adjusted to the prevailing disease patterns in various geographic areas.

Which Key Players Are Driving Competition In The Inactivated Influenza Vaccine Market?

Major companies operating in the inactivated influenza vaccine market are Pfizer Inc., Johnson & Johnson, Merck & Co. Inc., Sanofi S.A., AstraZeneca plc, Abbott Laboratories, Novartis International, GlaxoSmithKline plc, Viatris Inc., CSL, Zydus Lifesciences Limited, Sinovac Biotech Ltd., Bharat Biotech International Limited, Dalian Aleph Biomedical Co. Ltd., Hualan Biological Bacterin Co. Ltd, Changchun Biological, Jiangsu gdk Biotechnology Co., Ltd., KM Biologics, JoinHub Pharma, Pharmika India Private Limited.

Download The Full Report For Exclusive Market Findings:

https://www.thebusinessresearchcompany.com/report/inactivated-influenza-vaccine-global-market-report

Which Region Currently Holds The Largest Share Of The Inactivated Influenza Vaccine Market?

North America was the largest region in the inactivated influenza vaccine market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the inactivated influenza vaccine market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Version Of The Inactivated Influenza Vaccine Market Report:

https://www.thebusinessresearchcompany.com/customise?id=24251&type=smp

Browse Through More Reports Similar to the Global Inactivated Influenza Vaccine Market 2025, By The Business Research Company

Rabies Diagnostics Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/rabies-diagnostics-global-market-report

Dtp Vaccines Market 2025

https://www.thebusinessresearchcompany.com/report/dtp-vaccines-market

Adult Vaccines Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/adult-vaccines-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795